Patents by Inventor Thomas Haudebourg

Thomas Haudebourg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR PURIFYING A PYROLYSIS OIL IN ORDER TO UPGRADE IT BY STEAM-CRACKING
    Publication number: 20240076558
    Abstract: The invention relates to a method for purifying a pyrolysis oil originating from the pyrolysis of waste including plastics by liquid/liquid extraction. This extraction is performed by means of a polar solvent that is immiscible with pyrolysis oil, for which a recovery rate is obtained greater than or equal to 0.95, this recovery rate being defined as the ratio of the extract volume over the initial volume of solvent, this extract being a phase containing the solvent which is immiscible with pyrolysis oil, recovered after agitation then decantation of a mixture of one part by volume of solvent with twenty-five parts by volume of pyrolysis oil at atmospheric pressure and at a temperature of 20° C.
    Type: Application
    Filed: January 24, 2022
    Publication date: March 7, 2024
    Applicant: TotalEnergies OneTech
    Inventors: Thomas COUSTHAM, Marfiza Victoria BERRIO NAVARRO, Hélène COULOMBEAU-LEROY, Sébastien LEPLAT, Quentin LESUEUR, Didrik HAUDEBOURG
  • CYTOTOXIC ANTI-LAG-3 MONOCLONAL ANTIBODY AND ITS USE IN THE TREATMENT OR PREVENTION OF ORGAN TRANSPLANT REJECTION AND AUTOIMMUNE DISEASE
    Publication number: 20210317210
    Abstract: Cytotoxic anti-LAG-3 monoclonal antibodies or fragments thereof causing depletion of LAG-3+ activated T cells are described, as are related pharmaceuticals and methods of treating. Also described are related nucleic acid and protein sequences.
    Type: Application
    Filed: May 28, 2021
    Publication date: October 14, 2021
    Inventors: Thomas HAUDEBOURG, Frederic TRIEBEL, Bernard VANHOVE
  • CYTOTOXIC ANTI-LAG-3 MONOCLONAL ANTIBODY AND ITS USE IN THE TREATMENT OR PREVENTION OF ORGAN TRANSPLANT REJECTION AND AUTOIMMUNE DISEASE
    Publication number: 20190135916
    Abstract: Cytotoxic anti-LAG-3 monoclonal antibodies or fragments thereof causing depletion of LAG-3+ activated T cells are described, as are related pharmaceuticals and methods of treating. Also described are related nucleic acid and protein sequences.
    Type: Application
    Filed: December 7, 2018
    Publication date: May 9, 2019
    Inventors: Thomas HAUDEBOURG, Frederic TRIEBEL, Bernard VANHOVE
  • CYTOTOXIC ANTI-LAG-3 MONOCLONAL ANTIBODY AND ITS USE IN THE TREATMENT OR PREVENTION OF ORGAN TRANSPLANT REJECTION AND AUTOIMMUNE DISEASE
    Publication number: 20160176965
    Abstract: Cytotoxic anti-LAG-3 monoclonal antibodies or fragments thereof causing depletion of LAG-3+ activated T cells are described, as are related pharmaceuticals and methods of treating. Also described are related nucleic acid and protein sequences.
    Type: Application
    Filed: December 16, 2015
    Publication date: June 23, 2016
    Inventors: Thomas Haudebourg, Frederic Triebel, Bernard Vanhove
  • Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
    Patent number: 9244059
    Abstract: Cytotoxic anti-LAG-3 monoclonal antibodies or fragments thereof causing depletion of LAG-3+ activated T cells are described, as are related pharmaceuticals and methods of treating. Also described are related nucleic acid and protein sequences.
    Type: Grant
    Filed: June 25, 2010
    Date of Patent: January 26, 2016
    Assignees: Immutep Parc Club Orsay, Inserm—Institut National De La Sante Et De La Recherche Medicale
    Inventors: Frederic Triebel, Bernard Vanhove, Thomas Haudebourg
  • CYTOTOXIC ANTI-LAG-3 MONOCLONAL ANTIBODY AND ITS USE IN THE TREATMENT OR PREVENTION OF ORGAN TRANSPLANT REJECTION AND AUTOIMMUNE DISEASE
    Publication number: 20110070238
    Abstract: Cytotoxic anti-LAG-3 monoclonal antibodies or fragments thereof causing depletion of LAG-3+ activated T cells are described, as are related pharmaceuticals and methods of treating. Also described are related nucleic acid and protein sequences.
    Type: Application
    Filed: June 25, 2010
    Publication date: March 24, 2011
    Applicants: IMMUTEP PARC CLUB ORSAY, INSERM - INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: FREDERIC TRIEBEL, BERNARD VANHOVE, THOMAS HAUDEBOURG
  • CYTOTOXIC ANTI-LAG-3 MONOCLONAL ANTIBODY AND ITS USE IN THE TREATMENT OR PREVENTION OF ORGAN TRANSPLANT REJECTION AND AUTOIMMUNE DISEASE
    Publication number: 20100233183
    Abstract: The present invention concerns a molecule binding to LAG-3 protein and causing depletion of LAG-3? activated T cells particularly said molecule is a cytotoxic anti-LAG-3 monoclonal antibody or fragment thereof. It also concerns a method of treating or preventing organ transplant rejection or autoimmune diseases in a mammal comprising administering to said mammal a therapeutically effective amount of said antibody.
    Type: Application
    Filed: April 30, 2008
    Publication date: September 16, 2010
    Inventors: Frederic Triebel, Bernard Vanhove, Thomas Haudebourg